When tirzepatide’s SURPASS and SURMOUNT trial data were published, endocrinologists faced an uncomfortable realization: a single molecule had outperformed every existing diabetes and obesity therapy in head-to-head comparisons — including semaglutide, the previous standard-bearer. The reason wasn’t a refinement of GLP-1 agonism. It was the deliberate addition of a second incretin receptor target, GIP, that pharmacologists had previously written off as therapeutically inert.
What Is Tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide that simultaneously activates two incretin hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Developed by Eli Lilly and marketed as Mounjaro for type 2 diabetes (FDA approval May 2022) and Zepbound for chronic weight management (FDA approval November 2023), it was the first-in-class dual incretin receptor agonist to reach clinical use.[1]
Structurally, tirzepatide is based on the native GIP sequence rather than GLP-1, with modifications including a C20 fatty diacid moiety that binds albumin to extend half-life to approximately 5 days, enabling once-weekly subcutaneous dosing. The molecule was engineered with imbalanced agonism — exhibiting full GIP receptor potency but biased, lower-potency GLP-1 receptor activation that mimics native GLP-1 signaling kinetics.[2]
How Tirzepatide Works
GLP-1 Receptor Activation: Like semaglutide and liraglutide, tirzepatide stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite centers to reduce food intake. This pathway accounts for much of the glycemic and satiety effects shared with single-receptor GLP-1 agonists.[2]
GIP Receptor Activation: The GIP component is what distinguishes tirzepatide pharmacologically. GIP receptor agonism enhances insulin secretion synergistically with GLP-1, but its more interesting effects occur in adipose tissue, where GIP signaling improves lipid buffering, increases adipocyte insulin sensitivity, and may facilitate energy expenditure. GIP also appears to attenuate the nausea associated with GLP-1 agonism by acting on central nervous system circuits in the area postrema.[3]
Synergistic Metabolic Effects: The combined activation produces effects that exceed the sum of single-pathway agonism. Preclinical work demonstrated that GIP-GLP-1 co-agonism produces greater weight loss, improved glucose tolerance, and superior reduction in adiposity compared to GLP-1 monoagonism at equivalent doses — findings that translated directly to human trials.[2]
Clinical Evidence
SURPASS Program (Type 2 Diabetes): The SURPASS-2 trial, published in The New England Journal of Medicine in 2021, directly compared tirzepatide (5, 10, or 15 mg weekly) against semaglutide 1 mg weekly in 1,879 patients with type 2 diabetes. At 40 weeks, tirzepatide reduced HbA1c by 2.01–2.30% versus 1.86% for semaglutide, with the highest dose producing weight loss of 11.2 kg compared to 5.7 kg for semaglutide.[4]
SURMOUNT-1 (Obesity): The pivotal SURMOUNT-1 trial enrolled 2,539 adults with obesity (BMI ≥30) or overweight with at least one weight-related comorbidity, but without diabetes. Published in The New England Journal of Medicine in 2022, the trial showed mean weight reductions of 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses respectively over 72 weeks, compared to 3.1% with placebo. Approximately 57% of participants on the highest dose achieved ≥20% weight loss — magnitudes previously seen only with bariatric surgery.[5]
SURMOUNT-2 (Obesity with Type 2 Diabetes): In patients with both obesity and type 2 diabetes — a population historically resistant to weight loss interventions — SURMOUNT-2 demonstrated mean weight loss of 12.8% and 14.7% at the 10 and 15 mg doses over 72 weeks. This represented roughly double the weight loss typically observed with semaglutide 2.4 mg in comparable diabetic populations.[6]
Cardiometabolic and Hepatic Effects: Beyond weight and glucose, tirzepatide produces clinically meaningful reductions in systolic blood pressure (6–8 mmHg), triglycerides (20–25%), and waist circumference. Sub-studies have demonstrated reduction in liver fat content by approximately 30–50% in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), suggesting therapeutic potential beyond the current FDA-approved indications.[6]
Safety Profile
The safety profile of tirzepatide largely mirrors that of GLP-1 receptor agonists, with gastrointestinal adverse events predominating. Across the SURPASS and SURMOUNT trials, nausea (22–33%), diarrhea (16–22%), and vomiting (8–13%) were the most commonly reported events. The majority were mild to moderate, occurred during dose escalation, and resolved with continued therapy. Discontinuation rates due to adverse events ranged from 4–7% across pivotal trials.[4][5]
Important precautions mirror those of the GLP-1 class: tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent data, contraindicating use in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pancreatitis has been reported, though causality remains debated. Acute kidney injury, primarily related to volume depletion from gastrointestinal effects, requires monitoring. Gallbladder-related events occur at modestly increased frequency, consistent with rapid weight loss.
Hypoglycemia is rare in monotherapy but increases substantially when tirzepatide is combined with sulfonylureas or insulin, often necessitating dose reduction of those agents at initiation.
Tirzepatide vs Single-Receptor GLP-1 Agonists
Glycemic Efficacy: In the only published head-to-head trial against semaglutide (SURPASS-2), tirzepatide demonstrated superior HbA1c reduction at all three doses. Indirect comparisons against dulaglutide and liraglutide consistently favor tirzepatide for glycemic outcomes.[4]
Weight Loss: The most clinically striking difference is in weight reduction. Semaglutide 2.4 mg (Wegovy) produces approximately 15% weight loss in non-diabetic obesity (STEP-1 trial), while tirzepatide 15 mg produces approximately 21% — a roughly 40% greater effect. The SURMOUNT-5 trial, presented in 2025, was the first direct head-to-head comparison and confirmed tirzepatide’s superiority for weight loss in non-diabetic obesity.[5]
Tolerability: Despite producing greater weight loss, tirzepatide has not demonstrated meaningfully worse gastrointestinal tolerability than semaglutide in head-to-head data. The hypothesis that GIP co-agonism attenuates GLP-1-mediated nausea remains plausible but is not yet definitively proven in humans.[3]
Cardiovascular Outcomes: This is where the comparison remains incomplete. Semaglutide has demonstrated cardiovascular benefit in the SUSTAIN-6 and SELECT trials. Tirzepatide’s dedicated cardiovascular outcomes trial, SURPASS-CVOT, comparing it directly to dulaglutide, is ongoing with results expected in 2025. Until then, cardiovascular risk reduction with tirzepatide is presumed but not proven to the same standard.
Practical Considerations: Both agents are administered weekly via subcutaneous injection. Cost, insurance coverage, and supply availability have driven much of the real-world prescribing pattern, with both molecules experiencing periods of severe shortage since 2022. The emergence of compounded versions — and the FDA’s evolving regulatory position on them — has further complicated the access landscape.
The Broader Significance
Tirzepatide’s clinical success has triggered a wave of multi-receptor incretin development. Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, has produced weight loss exceeding 24% in early phase 2 data. Survodutide and CagriSema represent additional combination approaches. The therapeutic logic established by tirzepatide — that simultaneous, balanced activation of multiple metabolic receptors outperforms maximal single-receptor agonism — is reshaping the entire pipeline of metabolic drug development.
For clinicians, the practical implication is straightforward: tirzepatide currently represents the most potent pharmacologic option for both glycemic control in type 2 diabetes and chronic weight management. For the field of metabolic medicine, it represents proof-of-concept that incretin biology contains untapped therapeutic potential well beyond GLP-1 monotherapy.
References
- Min T, Bain SC. “The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.” Diabetes Therapy. 2021;12(1):143-157.
- Coskun T, et al. “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.” Molecular Metabolism. 2018;18:3-14.
- Samms RJ, Coghlan MP, Sloop KW. “How May GIP Enhance the Therapeutic Efficacy of GLP-1?” Trends in Endocrinology and Metabolism. 2020;31(6):410-421.
- Frías JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” New England Journal of Medicine. 2021;385(6):503-515.
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387(3):205-216.
- Garvey WT, et al. “Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.” The Lancet. 2023;402(10402):613-626.
